In HCS Pharma we strongly believe that 3D is the right way to improve drugs dicovery processes. It’s why we develop our 3D hydroscaffold matrix BIOMIMESYS® for 3D cell culture and we invest in 3D Read more…
For ethical and cost-related reasons, use of animals for the assessment of mode of action, metabolism and/or toxicity of new drug candidates has been increasingly scrutinized in research and industrial applications. Physiologically based pharmacokinetic (PBPK2) Read more…
BIOMIMESYS® Technology is a biomimetic hydrogel based on biofunctionalized hyaluronic acid with extracellular matrix components
culture + acquisition + analyse + visualization ... in 3D !
3D to 2D reduction with maximum accuracy
We were in Saint Malo for the first meeting on DYRKs related disease
3D cell models are now attracting a huge interest from scientists working both on toxicity and pharmacology assay development. They are considered more relevant at mimicking the in vivo situation. However, phenotypic assays on these models can be challenging, and are at least more complex.
At HCS Pharma, we work on many of the most exiting medical technologies !
ESTIV conference, named In Vitro Toxicology for Human Safety Assessment, takes place this week in Juan-les-Pins. This congress brings together a lot of toxicologists, from public and private, to discuss the last development of predictive in vitro models in safety Read more…
We just begin a test period of the Operetta "High Content Imaging System" from Perkin Elmer. First impressions are very goods, especially using confocal option for 3D imaging.